L. Kelland

Oncology · 2007

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 5 researchers here, as inferred from the citation graph.

Subfields

Whom L. Kelland trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Z. Siddik

Who trusts L. Kelland overall

  1. A. Tesnière
  2. L. Galluzzi
  3. A. Anselmo
  4. Raphael Ceccaldi
  5. Chunbai He
  6. Sumit Ghosh

Papers from L. Kelland's perspective

Ordered by how strongly the researchers L. Kelland trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. (New England Journal of Medicine)
  2. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
  3. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. (Journal of Clinical Oncology)
  4. THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
  5. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
  6. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer (British Journal of Cancer)
  7. Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA (Science Translational Medicine)
  8. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. (Molecular Pharmaceutics)
  9. Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer (New England Journal of Medicine)
  10. Expression profiling reveals off-target gene regulation by RNAi

Their papers